The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-26), Seagen's share price is $228.74. Seagen's Book Value per Share for the quarter that ended in Sep. 2023 was $13.52. Hence, Seagen's PB Ratio of today is 16.92.
Warning Sign:
Seagen Inc stock PB Ratio (=15.86) is close to 2-year high of 15.86
The historical rank and industry rank for Seagen's PB Ratio or its related term are showing as below:
SGEN'
s PB Ratio Range Over the Past 10 Years
Min: 9.41 Med: 14.66 Max: 15.86
Current: 15.86
During the past 13 years, Seagen's highest PB Ratio was 15.86. The lowest was 9.41. And the median was 14.66.
SGEN's PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 2.385
vs SGEN: 15.86
During the past 12 months, Seagen's average Book Value Per Share Growth Rate was -23.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 12.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 29.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 35.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Seagen was 62.30% per year. The lowest was -32.10% per year. And the median was 13.50% per year.
Back to Basics: PB Ratio
Seagen PB Ratio Historical Data
The historical data trend for Seagen's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Seagen's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Seagen's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Seagen's PB Ratio distribution charts can be found below:
* The bar in red indicates where Seagen's PB Ratio falls into.
Seagen PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Seagen's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Seagen PB Ratio Related Terms
Thank you for viewing the detailed overview of Seagen's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SGEN has been successfully added to your 